Use of molecular markers for predicting therapy response in cancer patients

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 151-159

  Duffy, Michael J ^a,b   O'Donovan, Norma ^c   Crown, John ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Biomarkers; Cancer; Personalized treatment; Predictive markers; Tumor markers

Indexed keywords

CETUXIMAB; CYTOCHROME P450 2D6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; K RAS PROTEIN; LAPATINIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT PROTEIN; TAMOXIFEN; TRASTUZUMAB;

ADRENALECTOMY; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; HUMAN; HYPOPHYSECTOMY; LUNG CANCER; LUNG NON SMALL CELL CANCER; OVARIECTOMY; REVIEW;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 79151486380     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.07.004     Document Type: Review

References (116)

1. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin Chem 2005, 51:494-503.
2. Walgren R.A., Meucci M.A., McLeod H.L. Pharmacogenomics discovery approaches: will the real genes please stand up?. J Clin Oncol 2005, 23:7342-7349.
3. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol 2005, 10:7350-7360.
4. Huang R.S., Ratain M.J. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009, 59:42-55.
5. Sawyers C.L. The cancer biomarker problem. Nature 2008, 452:548-552.
6. Duffy M.J. Estrogen receptors: role in breast cancer. Crit Rev Clin Lab Sci 2006, 43:325-347.
7. McGuire WL, Carbone PP, Sears ME, Escher GC. Estrogen receptors in human breast cancer: an overview: In: McGuire WL, Carbone PP, Vollner EP, editors. Estrogen receptors in human breast cancer, New York: Raven Press; 1975. p. 1-8.
8. Early Breast Cancer Trialist's Collaborative Group. Tamoxifen for early breast cancer: an overview of randomized trials. Lancet 1998;351:1451-67.
9. Early Breast Cancer Trialists' Collaborative Group (EBCTTG). Effect of chemotherapy and hormone therapy for early breast cancer on recurrence and 15-year survival: an overview of randomised trials. Lancet 2005;365:1687-1717.
10. ATAC Trialists Group. Results of the ATCC (Arimidex Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
11. Mauri D., Pavlidis N., Polyzos N.P., Ioannidis J.P. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006, 98:1285-1291.
12. Dowsett M., Cuzick J., Wale C., Howell T., Houghton J., Baum M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status. J Clin Oncol 2005, 23:7512-7517.
13. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007, 25:2006-2011.
14. Takei H., Suemasu K., Inoue K., et al. Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat 2008, 107:87-94.
15. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nature Rev Cancer 2009, 9:631-643.
16. Zilli M., Grassadonia A., Tinari N., Di Giacobbe A., Gildetti S., Giampietro J., et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta 2009, 179:62-81.
17. Horwitz K.B., McGuire W.L., Pearson O.H., Segaloff A. Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 1975, 189:726-727.
18. McGuire W.L. Steroid hormone receptors in breast cancer treatment strategy. Rec Prog Hormone Res 1980, 36:135-156.
19. Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., et al. Prognostic metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992, 10:1284-1291.
20. Dowsett M., Houghton J., Iden C., Salter J., Farndon J., A'Hern R., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006, 17:818-826.
21. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in 2 large breast cancer databases. J Clin Oncol 2003, 21:1973-1979.
22. Liu S., Chia S., Mehl E., et al. Progesterone receptor is a significant factor associated with clinical outcome and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010, 119:53-61.
23. Stendahl M., Rydén L., Nordenskjöld B., Jönsson P.E., Landberg G., Jirström K. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006, 12:4614-4618.
24. De Placido S., De Laurentiis M., Carlomagno C., Gallo C., Perrone F., Pepe S., et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003, 9:1039-1046.
25. De Laurentiis M., Arpino G., Massarelli E., Ruggiero A., Carlomagno C., Ciardiello F., et al. A meta-analysis of the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11:4741-4748.
26. Nicholson S., Sainsbury J.R., Halcrow P., Chambers P., Farndon J.R., Harris A.L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989, 1:182-185.
27. Giltnane J.M., Rydén L., Cregger M., Bendahl P.O., Jirström K., Rimm D.L. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol 2007, 25:3007-3014.
28. Foekens J., Look M.P., Peters H.A., van Putten W.L.J., Portengen H., Klijn J.G.M. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995, 87:751-756.
29. Meijer-van Gelder M.E., Look M.P., Peters H.A., Schmitt M., Brunner N., Harbeck N., et al. Urokinase-type plasminogen activator (uPA) system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004, 64:4563-4568.
30. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12:631-635.
31. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., et al. A multi-gene assay to predict recurrence of tamoxifen-treated node-negative breast cancer. N Engl J Med 2005, 347:2817-2826.
32. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834.
33. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
34. Jansen M.P.H.M., Sieuwerts A.M., Look M.P., Ritstier K., Meijer-van Gelder M.E., et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol 2007, 25:662-668.
35. Zhang Y., Sieuwerts A.M., McGreevy M., et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009, 116:303-309.
36. Conneely O.M., Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000, 65:571-577.
37. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., McDonnell D.P. Human progesterone A form is a cell and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 1993, 7:1244-1255.
38. Wen D.X., Xu Y.F., Mais D.E., Goldman M.E., McDonnell D.P. The A and B form of human progesterone receptor operate through distinct signalling pathways within target cells. Mol Cell Biol 1994, 14:8356-8364.
39. Hopp T.A., Weiss H.L., Hilsenneck S.G., Cui Y., Allred D.C., Horwitz K.B., et al. Breast cancer patients with progesterone receptor PR-A rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004, 10:2751-2760.
40. Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009, 9:576-586.
41. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
42. Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H. Clin Cancer Res Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer 2009;15:15-21.
43. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436.
44. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
45. Browne B.C., O'Brien N., Duffy M.J., Crown J., O'Donovan N. HER-2 signaling and inhibition in breast cancer. Current Cancer Drug Therapy 2009, 9:419-438.
46. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009, 14:320-368.
47. Hudis C.A. Trastuzumab, mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51.
48. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weakly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
49. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanised anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
50. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Eng J Med 2001, 344:783-792.
51. Demonty G., Bernard-Marty C., Puglisi F., Mancini I., Piccart M. Progress and new standards of care in the management of HER-2 positive breast cancer. Eur J Cancer 2007, 43:497-509.
52. Simon R., Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004, 10:6759-6763.
53. Dahabreh I.J., Linardou H., Siannis F., Fountzilas G., Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008, 13:620-630.
54. Paik S., Kim C., Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411.
55. Press M.F., Finn R.S., Cameron D., Di Leo A., Geyer C.E., Villalobos I.E., et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008, 14:7861-7870.
56. Arnould L., Arveux P., Couturier J., Gelly-Marty M., Loustalot C., Ettore F., et al. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res 2007, 13:6404-6409.
57. Slamon D., Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Sem Oncol 2001, 28(Suppl 3):13-19.
58. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
59. Kataoka Y., Mukohara T., Shimada H., Saijo N., Hirai M., Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010, 21:255-262.
60. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
61. Crowder R.J., Lombardi D.P., Ellis M.J. Successful targeting of ErbB2 receptors-is PTEN the key?. Cancer Cell 2004, 6:103-104.
62. Faratian D., Goltsov A., Lebedeva G., Sorokin A., Moodie S., Mullen P., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 2009, 69:6713-6720.
63. Lu Y, Zi X, Pollak M. Int J Cancer. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells 2004;108:334-41.
64. Scaltriti M., Rojo F., Ocaña A., Anido J., Guzman M., Cortes J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007, 99:628-638.
65. Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance Mol Cancer Ther 2009;8:2152-62.
66. Miyamoto S., Fukami T., Yagi H., et al. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res 2009, 29:823-830.
67. Peeters M., Price T., Van Laethem J.L. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. Oncologist 2009, 14:29-39.
68. Shankaran V., Obel J., Benson Al.B. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010, 15:157-167.
69. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
70. Allegra C.J., Jessup J.M., Somerfield M.R., Hamilton S.R., Hammond E.H., Hayes D.F., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
71. Di Nicolantonio F., Martini M., Molinari F., Sartore-Bianchi A., Arena S., Saletti P., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
72. Sartore-Bianchi A., Martini M., Molinari F., Veronese S., Nichelatti M., Artale S., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
73. Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007, 7:169-181.
74. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358(11):1160-1174.
75. Herbst R.S., Heymach J.V., Lippman S.M. Molecular origins of cancer, lung cancer. N Engl J Med 2008, 359(13):1367-1380.
76. Parra H.S., Cavina R., Latteri F., Zucali P.A., Campagnoli E., Morenghi E., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004, 19:208-212.
77. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D. Et all. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22:3238-3247.
78. Dahabreh I.J., Linardou H., Siannis F., Kosmidis P., Bafaloukos D., Murray S. Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010, 16:291-303.
79. Hammerman P.S., Janne P.A., Johnson B.E. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009, 15:7502-7509.
80. Mok T., Y-L W.U., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
81. Douillard J.Y., Shepherd F.A., Hirsh V., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
82. D'Addario G, Felip E. On behalf of the ESMO Guidelines Working Group. Non-small cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii39-ii40.
83. Azzoli C.G., Baker S., Temin S., et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
84. NCCN Practice Guidelines in non-small cell lung cancer. V.2.2010. [accessed 25.3.2010]. http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
85. Linardou I., Dahabreh D., Kanaloupiti F., Siannis D., Bafaloukos P., Kosmidis C., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962-972.
86. Engelman J.A., Jänne P.A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008, 14:2895-2899.
87. Kosaka T., Yatabe Y., Endoh H., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
88. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2:e73.
89. Kuang Y., Rogers A., Yeap B.Y., et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009, 15:2630-2636.
90. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
91. Karamouzis M.V., Konstantinopoulos P.A., Papavassiliou A.G. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009, 10:709-717.
92. Albain K.S., Paik S., van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays. Breast 2009, 18(Suppl 3):S141-S145. [Review].
93. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800. [Review].
94. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, ER-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
95. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
96. Straver M.E., Glas A.M., Hannemann J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
97. Knauer M., Mook S., Rutgers E.J.T., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010, 120:655-661.
98. Kok M., Linn S.C., Van Laar R.K., Jansen M.P., van den Berg T.M., Delahaye L.J., et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2009, 113:275-283.
99. Gennari A., Sormani M.P., Pronzato P., Puntoni M., Colozza M., Pfeffer U., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14-20.
100. Brase J.C., Schmidt M., Fischbach T., Sültmann H., Bojar H., Koelbl H., et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res 2010, 16:2391-2401.
101. Esteva F.J., Hortobagyi G.N. Topoisomerase II{alpha} amplification and anthracycline-based chemotherapy: the jury is still out. J Clin Oncol 2009, 27:3416-3417.
102. Mano M.S., Rosa D.D., de Azambuja E., Ismael G.F.V., Durbecq V. The 17q12-q21 amplicon: her2 and topoisomerase-IIa and their importance to the biology of solid tumours. Cancer Treat Rev 2007, 33:64-77.
103. Tanner M., Isola J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P. Topoisomerase IIa gene amplification predicts favourable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: results from the randomised Scandinavian breast group trial 9401. J Clin Oncol 2006, 16:2428-2436.
104. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
105. Rouzier R., Rajan R., Wagner P., Hess K.R., Gold D.L., Stec J., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005, 102:8315-8320.
106. Bhat K.M.R., Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007, 13:2849-2854.
107. Andre F., Hatzis C., Anderson K., Sitiriou C., Mazouni C., Mejia J., et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-2067.
108. Ejlertsen B., Jensen M.B., Nielsen K.V., Balslev E., Rasmussen B.B., Willemoe G.L., et al. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J Clin Oncol 2010, 28:984-990.
109. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., et al. Kinase mutation and imatinib response in patients with metastatic gastrointestinal stromal tumors. J Clin Oncol 2003, 21:4342-4349.
110. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGRFA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004, 40:689-695.
111. Chen S, Zhang J, Wang R, Luo X, Chen H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer; in press, PMID 20541281.
112. Kelleher FC, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer; in press, PMID 20451371.
113. Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
114. Hegi M.E., Diserens A.-C., Gorlia T., Hamou M.-F., de Tribolet N., Weller M., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
115. Jørgensen J.T. Targeted HER2 treatment in advanced gastric cancer. Oncology 2010, 78:26-33.
116. Boland C.R., Goel A. Microsatellite in colorectal cancer. Gastroenterology 2010, 138:2073-2087.